A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Clinically grounded, game-based and always available — MIRDC’s AI system is redefining how children learn to communicate.
Updated
January 8, 2026 6:32 PM
A child practicing with a speech therapist. PHOTO: FREEPIK
Speech and language delays are common, yet access to therapy remains limited. In Taiwan, only about 2,200 licensed speech-language pathologists serve hundreds of thousands of children who need support—especially those with autism spectrum disorders or significant communication challenges. As a result, many children miss crucial periods of language development simply because help isn’t available soon enough.
MIRDC’s new AI-powered interactive speech therapy system aims to close that gap. Instead of focusing solely on articulation, it targets a wider range of language skills that many children struggle with: oral expression, comprehension, sentence building and conversational ability. This makes it a more complete tool for childhood speech and language development.
The system combines game-based learning, AI-driven guidance and automated language assessment into one platform that can be used both in clinics and at home. This integrated design helps children practice more consistently, providing therapists and parents with clearer insight into their progress.
The interactive game modules are built around clinically validated therapy methods. Imitation exercises, picture cards, storybooks and conversational prompts are turned into structured game levels, each aligned with a specific developmental goal. This step-by-step approach helps children move from simple naming tasks to more complex comprehension and response skills, all within a sequenced curriculum.
A key differentiator is the system’s real-time AI speech interpretation. As the child talks, the AI analyzes the response and generates tailored therapeutic cues—such as imitation, modeling, expansion or extension—based on the conversation. These are the same strategies used by speech-language pathologists, but now children can access them continuously, supporting more effective at-home practice and reducing long gaps between sessions.
After each session, the system automatically conducts a data-driven language assessment using 20 objective indicators across semantics, syntax and pragmatics. This provides clinicians and families with measurable, easy-to-understand reports that show how the child is progressing and which skills need more attention—something many traditional tools do not offer.
By offering a personalized, scalable and clinically grounded solution, MIRDC’s AI therapy system helps address the ongoing shortage of speech-language services. It doesn’t replace therapists; instead, it extends their reach, allows for more consistent practice and helps families support their child’s communication at home.
As an added recognition of its impact, the system recently earned two R&D 100 Awards, including the Silver Award for Corporate Social Responsibility. But at its core, the project remains focused on a simple mission: making high-quality speech therapy accessible to every child who needs a voice.